Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study

• Published in: Journal of the American College of Cardiology 2002-04, Vol.39 (7), p.1133-1138
• Main Authors: HAIM, Moti, TANNE, David, BOYKO, Valentina, RESHEF, Tamar, GOLDBOURT, Uri, LEOR, Jonathan, MEKORI, Yoseph A, BEHAR, Solomon
• Format: Article
• Language: English
• Subjects: Angina pectoris; Bezafibrate - therapeutic use; Biological and medical sciences; Cardiology; Cardiology. Vascular system; Cardiovascular disease; Case-Control Studies; Cholesterol; Coronary Disease - blood; Coronary Disease - epidemiology; Coronary heart disease; Female; Follow-Up Studies; Heart; Heart attacks; Humans; Hypolipidemic Agents - therapeutic use; Intercellular Adhesion Molecule-1 - blood; Lipids; Logistic Models; Male; Medical sciences; Middle Aged; Myocardial Infarction - prevention & control; Prospective Studies; Risk Assessment; Time Factors
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/S0735-1097(02)01728-X

The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD). Increased sICAM-1 concentration has been shown to be associated with the incidence of CHD in healthy persons. Its significance in patients with CHD has been scarcely investigated. We designed a prospective, nested case-control study. Sera were collected from patients with CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in reducing coronary events. We measured baseline sICAM-1 concentration in the sera of patients who developed subsequent cardiovascular events (cases: n = 136) during follow-up (mean: 6.2 years) and in age- and gender-matched controls (without events: n = 136). Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p < 0.05). Each 100 ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of coronary events. Soluble ICAM-1 concentration in the highest quartile (>394 ng/ml) was associated with significantly higher odds of coronary events (compared with the lowest quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding fibrinogen and total white blood cell count to the multivariate model, the relative odds were 2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively. Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future coronary events independent of other traditional risk factors.